Table: Kyowa Kirin 6-MTH group results (IFRS)
Jul 31 (Reuters)-
Kyowa Kirin Co., Ltd.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Jun 30, 2025 Jun 30, 2024 Dec 31, 2025
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 230.65 232.97 478.00
(-1.0 pct) (+16.9 pct) (-3.5 pct)
Operating
Pretax 21.98 46.52 74.00
(-52.8 pct) (+78.6 pct) (-11.3 pct)
Net 16.32 37.78 57.00
(-56.8 pct) (+74.5 pct) (-4.8 pct)
EPS Basic 31.18 yen 70.76 yen 108.91 yen
EPS Diluted 31.18 yen 70.75 yen
Ann Div 58.00 yen 60.00 yen
-Q2 Div 30.00 yen 29.00 yen
-Q4 Div 29.00 yen 30.00 yen
NOTE - Kyowa Kirin Co., Ltd..
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4151.T
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia